HOME
Today we wrapped up a successful 2nd Review Meeting for NeoVasculoStop.
A huge thank you to our Officer, Reviewers, and all Partners for their invaluable contributions and for the great presentations. Together, we’re making great strides in advancing our project’s vision and impact!
Stay tuned for more exciting results creating a brighter future!
In a significant stride for retinopathy treatment, the NeoVasculoStop consortium has successfully reached the milestone of Month 30 entitled “Identification of the Two Best Inhibitors.” Correspondingly, EYE1118 has been selected as an efficient promising lead compound and EYE1090 as the follow up molecule. This achievement marks a critical phase in the project aimed at developing advanced inhibitors for targeted disease treatment.
We are optimistic about the future applications of these results in treating a complex group of diseases.
We’re thrilled to share that Experimentica, our partner, significantly impacted the recent ARVO2024. Their presence and contributions were invaluable, making the event a huge success.
Seeing our partners thriving and driving innovation in their respective fields is always inspiring. Collaborations like these are instrumental in pushing boundaries and achieving remarkable results.
Congratulations to the Experimentica team for their outstanding performance at the ARVO2024! Looking forward to more fruitful collaborations ahead.
We propose an oral medication that will effectively deliver any therapeutic molecule to the eye. Our approach aims to reduce adverse effects, help patients maintain their vision, lower treatment costs, and decrease the required therapeutic dose.
We aim to demonstrate the proof-of-concept of the proposed strategy by modifying inhibitors of the vascular endothelial growth factor receptor (VEGFR) that is a key mediator of angiogenesis and an established drug target for treating retinopathies.
NeoVasculoStop establishes the foundation for a new future technology. The core idea can later be applied to any other ocular disease, provided that an ocular target molecule (such as a receptor, enzyme, or channel) can be identified. We believe that the chemical properties of the medication offer significant advantages over traditional treatments. Our ambition is strongly motivated by the exceptional societal impact that the new product could have globally.